WASHINGTON, May 20 /PRNewswire-USNewswire/ -- Fuisz Tobacco today announces the results of a cross-over clinical study comparing the absorption of nicotine from the use of Fuisz Tobacco's dissolving tobacco strip and the use of a nicotine 2mg chewing gum -- the study's control.
The results demonstrate extraordinary nicotine bioavailability for the Fuisz Tobacco strip. A Fuisz Tobacco strip containing 75 mg's of tobacco delivered substantially higher peak nicotine plasma concentration than the 2 mg nicotine chewing gum control product. This suggests that the Fuisz Tobacco strip delivers nicotine more than five times more effectively than the SNUS tobacco format, which is considered to represent the most efficacious smokeless tobacco format for nicotine delivery currently available.
The study design was based upon the Lunell study of Swedish SNUS nicotine absorption. The Lunell study is part of the so called Gothiatek(R) standards developed by leading SNUS marketer Swedish Match.
Joseph Fuisz, Fuisz Tobacco's Managing Member commented: "These study results represent a remarkable advance for smokeless tobacco. By delivering tobacco satisfaction from a dramatically smaller amount of tobacco, we can substantially lower the amount of tobacco used in the adult consumer friendly Fuisz Tobacco strip. This news should be welcomed by the harm reduction community, the tobacco industry, and adult smokers alike."
Fuisz Tobacco's Founding Member, Richard Fuisz, M.D., stated: "We have a new concept here. The Fuisz Tobacco strip is not a cigarette and yet the user gets nicotine from its tobacco. This is not a pouch that does not efficiently transfer nicotine and then must be removed from the mouth and is environmentally as damaging as a cigarette. This gives off no smoke and is unaffected by smoking bans. This is not an ill tasting lozenge. This is in fact the new way for adult tobacco users to gain satisfaction in a simple straightforward manner. Easier to use than SNUS, a small strip is simply placed in the cheek and allowed to dissolve."
Joseph Fuisz, continued: "It is important to understand that the Fuisz Tobacco strip's super bioavailability is used to lower the amount of tobacco contained in our smokeless product, and not to develop ever-higher nicotine plasma concentrations. The Fuisz tobacco strip offers not only excellent tobacco satisfaction but is a great tasting product that appeals greatly to the vast majority of adult smokers, most of whom are not inclined to use existing smokeless tobacco products."
The clinical study was performed by an independent contract research organization that serves the pharmaceutical industry.
The Fuisz Tobacco smokeless tobacco product is a tobacco containing sheet, similar in appearance to a Listerine(R) PocketPak(R) breath strip but substantially thicker and taking longer to dissolve. The Fuisz Tobacco strip is spitless and dissolves entirely in the cheek. This means that the product can be discretely consumed in a social setting without residue to remove from the mouth after use -- unlike traditional smokeless tobacco products. Fuisz Tobacco's tobacco strip technology is protected by multiple patents pending and licenses.
Fuisz Tobacco is a private company. Its founding partner, Richard C. Fuisz, M.D., is a noted pharmaceutical inventor, including in the thin film drug delivery, quick dissolve tablet, taste masking and controlled release fields (http://www.en.wikipedia.org/wiki/Richard_Fuisz). Fuisz Tobacco's managing partner, Joseph Fuisz, is a corporate lawyer and is a named inventor on over forty thin film drug delivery patents issued and pending. Mr. Fuisz previously served as Senior Vice President for Business Development of MonoSol Rx (http://www.monosolrx.com). He is a graduate of Yale College and the Columbia Law School.
|SOURCE Fuisz Tobacco|
Copyright©2008 PR Newswire.
All rights reserved